symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
ONCT,0.3138,1.344354,176407,18504441,0,0.26-1.33,0.0258,"Oncternal Therapeutics, Inc.",USD,0001260990,US68236P1075,68236P107,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.oncternal.com,"Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.","Dr. James B. Breitmeyer M.D., Ph.D.",Healthcare,US,30,858 434 1113,12230 El Camino Real,San Diego,CA,92130,1.84029,2.86029,https://financialmodelingprep.com/image-stock/ONCT.png,2004-02-03,False,False,True,False,False
